Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
Below the Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
"Cohance Lifesciences being an integrated API and CDMO manufacturer with a strong vintage shall demonstrate strong synergies post its merger with Suven Pharma, a world-class manufacturer of pharmaceuticals and fine chemical intermediates. This merger will provide operational efficiences and end-to-end product development and delivery for the end-customer with strong raw material sourcing. This merger will create tremendous shareholder value. Also, merging synergistic privately owned companies with their publicly owned company provides private equity firms a clear path to exit."
Above views are of the author and not of the website kindly read disclaimer
Tag News
Gold Advances to $2,750 Amid Trade Uncertainty and Rate Bets by Amit Gupta, Kedia Advisory
